Bristol Myers (BMY) Offering Possible 10.62% Return Over the Next 6 Calendar Days

view original post

Bristol Myers’s most recent trend suggests a bearish bias. One trading opportunity on Bristol Myers is a Bear Call Spread using a strike $60.00 short call and a strike $65.00 long call offers a potential 10.62% return on risk over the next 6 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $60.00 by expiration. The full premium credit of $0.48 would be kept by the premium seller. The risk of $4.52 would be incurred if the stock rose above the $65.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Bristol Myers is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Bristol Myers is bearish.

The RSI indicator is at 25.45 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Bristol Myers

5 Warren Buffett Stocks to Buy Hand Over Fist for the Fourth Quarter
Fri, 08 Oct 2021 10:06:00 +0000
If you’ve ever wondered why Wall Street and retail investors pay such close attention to billionaire Warren Buffett, it’s because he has an impeccable moneymaking track record. Since taking over as CEO of Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) in 1965, the Oracle of Omaha has overseen the creation of nearly $600 billion in market value for shareholders, and delivered an average annual return of 20% for the company’s Class A shares. Riding Buffett’s coattails has long been a profitable venture.

Is an Acquisition of Acceleron a Smart Move for Merck?
Fri, 08 Oct 2021 10:05:00 +0000
First, there were rumors that Merck (NYSE: MRK) might acquire Acceleron Pharma (NASDAQ: XLRN). Then those rumors were confirmed, with the big pharma company announcing plans to buy Acceleron for $11.5 billion. In this Motley Fool Live video recorded on Sept. 29, 2021 (one day before Merck’s announcement of the deal), Motley Fool contributors Keith Speights and Brian Orelli discuss whether acquiring Acceleron would be a smart move for Merck.

BRISTOL MYERS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company – BMY
Fri, 08 Oct 2021 00:20:00 +0000
NEW ORLEANS, October 08, 2021–Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 6, 2021 to file lead plaintiff applications in a securities class action lawsuit against Bristol-Myers Squibb Company (“BMS” or “the Company”) (NYSE: BMY), if they received Contingent Value Rights (“CVRs”) (NYSE: BMY.RT) in exchange for their shares of Celgene Corporation (NASDAQ: CELG) pursuant to BMS’ acquisiti

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
Thu, 07 Oct 2021 21:45:09 +0000
In the latest trading session, Bristol Myers Squibb (BMY) closed at $59.01, marking a -0.3% move from the previous day.

Bristol Myers’ TYK2 Inhibitor Disappoints In Mid-Stage Ulcerative Colitis Study
Thu, 07 Oct 2021 14:23:21 +0000
Bristol Myers Squibb & Co (NYSE: BMY) has announced topline data from the Phase 2 LATTICE-UC study evaluating deucravacitinib in moderate to severe ulcerative colitis (UC). The study did not meet the primary efficacy endpoint of clinical remission at Week 12 nor secondary efficacy endpoints. The safety profile of deucravacitinib was consistent with previously reported studies in psoriasis and psoriatic arthritis, and no new safety signals were observed. The Company will complete a full review of

Be Sociable, Share!

Related Posts